NCT00500929 (MiniMetrxics) is a Phase 2 clinical trial of CMI X-11S in Heart Disease, sponsored by Cardiometabolics.

Who is sponsoring NCT00500929?

NCT00500929 is sponsored by Cardiometabolics.

What drugs are being tested in NCT00500929?

Interventions in NCT00500929: CMI X-11S.

What condition does NCT00500929 study?

NCT00500929 studies Heart Disease.

Is NCT00500929 still recruiting?

NCT00500929 is currently completed. Last updated 23 March 2009.

Last reviewed 2009-03-23 · How we verify

NCT00500929: MiniMetrxics

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mini-Metrxics: A Single-Centre, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Clinical Trial of CMI X-11S in Higher Risk Geriatric Patients Undergoing Open-Heart Surgical Procedures (OHSP)

Completed Phase 2 Last updated 23 March 2009

What this trial tests

Phase 2 trial testing CMI X-11S in Heart Disease in 80 participants. Completed in 1 May 2008.

Timeline

1 July 2007

Primary endpoint
1 April 2008

1 May 2008

Quick facts

Lead sponsor	Cardiometabolics
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	80
Start date	1 July 2007
Primary completion	1 April 2008
Estimated completion	1 May 2008
Sites	1 location across Canada

Drugs / interventions tested

CMI X-11S — full drug profile →

Conditions studied

Heart Disease — all drugs for Heart Disease →

Sponsor

Cardiometabolics — full company profile →

Who can join

70 and older, any sex, with Heart Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

ICU Time
Time frame: 30 to 45 days post-surgery

Sponsor's own description

To provide information on parameters needed to design a subsequent Phase III confirmatory trial and to assess the safety and efficacy of the acute use of CMI X-11S in high-risk geriatric patients undergoing open-heart surgical procedures (OHSP) requiring cardio-pulmonary bypass.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Disease

Currently open trials in the same condition.

NCT07380243 — Pathways to Prevention Food-is-Medicine Trial · NA · recruiting
NCT07126587 — Healthy Living Anson Study · NA · recruiting
NCT06927739 — Focused Orticumab Research for Treating Inflammation in Coronary Arteries · Phase 2 · recruiting
NCT06420960 — Diagnostic Efficacy of Connected WAtch ECG Versus External Holter ECG · NA · recruiting
NCT06896318 — Virtual Reality-Supported Cardiac Rehabilitation: Psychological, Functional, and Physiological Perspectives · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00500929 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cardiometabolics
Last refreshed: 23 March 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00500929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing